Adlinda Alip

机构：University of Malaya · ORCID：0000-0003-4744-4533

发表论文 57 篇 · 总被引 1459 次 · h-index 12

代表论文

• Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC (2024 · New England Journal of Medicine · 被引 453)
• Overall Survival with Amivantamab–Lazertinib in EGFR -Mutated Advanced NSCLC (2025 · New England Journal of Medicine · 被引 136)
• Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA (2024 · Annals of Oncology · 被引 101)
• LBA14 Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results from MARIPOSA, a phase III, global, randomized, controlled trial (2023 · Annals of Oncology · 被引 85)
• 4O: Amivantamab plus lazertinib vs osimertinib in first-line (1L) EGFR-mutant (EGFRm) advanced NSCLC: Final overall survival (OS) from the phase III MARIPOSA study (2025 · Journal of Thoracic Oncology · 被引 46)
• Barriers of and strategies for shared decision‐making implementation in the care of metastatic breast cancer: A qualitative study among patients and healthcare professionals in an Asian country (2022 · Health Expectations · 被引 28)